Company Performance - Schrodinger, Inc. reported a quarterly loss of $0.82 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, and compared to a loss of $0.76 per share a year ago, indicating a negative earnings surprise of -15.49% [1] - The company posted revenues of $59.55 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.81%, and showing significant growth from year-ago revenues of $36.6 million [2] - Over the last four quarters, Schrodinger has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] Stock Outlook - Schrodinger shares have increased approximately 22.1% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.76 for the coming quarter and -$2.47 for the current fiscal year [4][7] - The estimate revisions trend for Schrodinger is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Schrodinger belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Outset Medical, Inc. reported a quarterly loss of $3.24 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.97, representing an earnings surprise of -234.02% [1] - The company posted revenues of $29.75 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.49%, and showing an increase from $28.17 million in the same quarter last year [2] - Over the last four quarters, Outset Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Outset Medical shares have declined approximately 30.7% since the beginning of the year, in contrast to the S&P 500's decline of -4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.95 on revenues of $29.5 million, and for the current fiscal year, it is -$3.92 on revenues of $120.09 million [7] Industry Outlook - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Security systems manufacturer Napco Security Technologies, Inc. (NASDAQ: NSSC), already facing a securities class action lawsuit stemming from earlier disclosures about its distribution network, reported mixed results for its third quarter of fiscal year 2025 on May 5. This new development underscores the challenges the company is currently navigating amidst ongoing legal scrutiny. Hagens Berman urges Napco investors who suffered substantial losses to submit y ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Gr ...

Sabre (SABR) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Brian Evans - SVP, Investor Relation & TreasurerKurt Ekert - President & Chief Executive OfficerMike Randolfi - Chief Financial OfficerJed Kelly - Managing Director - Equity ResearchJames Goodall - Director & Head - Transport & Leisure Conference Call Participants Victor Cheng - AnalystJoshua Baer - AnalystJeff Harlib - AnalystNone - AnalystAlex Irving - Analyst Operator Good morning, and welcome to the Sabre First Quarter twen ...

Sabre (SABR) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Brian Evans - SVP, Investor Relation & TreasurerKurt Ekert - President & Chief Executive OfficerMike Randolfi - Chief Financial OfficerJed Kelly - Managing Director - Equity ResearchJames Goodall - Director & Head - Transport & Leisure Conference Call Participants Victor Cheng - AnalystJoshua Baer - AnalystJeff Harlib - AnalystNone - AnalystAlex Irving - Analyst Operator Good morning, and welcome to the Sabre First Quarter twen ...

Sabre (SABR) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Good morning, and welcome to the Sabre First Quarter twenty twenty five Earnings Conference Call. My name is Rivka, and I'll be your operator. As a reminder, please note today's call is being recorded. I will now turn the call over to the Senior Vice President, Investor Relations and Treasurer, Brian Evans. Please go ahead, sir. Speaker1 Good morning, and welcome to our first quarter twenty twenty five earnings call. This morning, we issue ...

TWIN DISC, INC Investor Presentation DISCLOSURES Safe Harbor Statement This presentation contains statements that are forward-looking within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's current expectations that are based on assumptions that are subject to risks and uncertainties. Actual results may vary because of variations between these assumptions and actual performance. Investors are referred to Twin Disc's fiscal year 2024 An ...

Company Performance - Lumentum reported quarterly earnings of $0.57 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, and up from $0.29 per share a year ago, representing an earnings surprise of 14% [1] - The company achieved revenues of $425.2 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.45%, and an increase from $366.5 million year-over-year [2] - Over the last four quarters, Lumentum has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Lumentum shares have declined approximately 24.8% since the beginning of the year, compared to a 3.9% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.65 for the coming quarter and $1.76 for the current fiscal year [4][7] Industry Context - The Lasers Systems and Components industry, to which Lumentum belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Lumentum's stock performance [5]

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...